期刊文献+

Ⅱ/Ⅲ期食管癌放化疗的影像学评价对预后的影响

下载PDF
导出
摘要 目的:分析影像学评价对食管癌Ⅱ/Ⅲ期放化疗预后的影响。方法:选取2021年9月—2022年2月于济宁市第三人民医院复诊的20例食管癌病例展开研究,病例来自影像存储与传输系统(picture archiving and communication system,PACS),患者均经临床确诊为食管癌Ⅱ/Ⅲ期,回顾性分析其全部的临床资料,所有对象均接受简单调强技术或三维适形放疗。分析不完全缓解(not in complete remission,NCR)与完全缓解(complete remission,CR)在实体瘤疗效评价标准(response evaluation criteria for solid tumors,RECIST)(NrCR、rCR)、X射线造影(NxCR、xCR)、病理(NpCR、pCR)等评价方法下的总生存率,并展开Logistic多因素分析。结果:20例患者rCR率、xCR率、pCR率分别为35.0%(7/20)、45.0%(9/20)、30.0%(6/20)。对比在不同评价方法中NCR与CR者的1、3、5年总生存率,NrCR与rCR、NxCR与xCR、NpCR与pCR之间的差异显著(P<0.05)。Logistic多因素分析,患者独立预后因素为pCR(95%CI:0.199~0.553,HR=0.342,P<0.05)。结论:放化疗的食管癌Ⅱ/Ⅲ期患者以治疗后pCR为判断疗效金标准,且其属于独立预后因素,可用于指导判断临床疗效,且与NrCR、NxCR相比,rCR、xCR显著提升了患者生存率。
出处 《影像研究与医学应用》 2022年第11期185-187,共3页 Journal of Imaging Research and Medical Applications
  • 相关文献

参考文献8

二级参考文献55

  • 1李夷民,林勤,王丽琛,孙龙,戴明明,罗作明,郑华,赵龙,吴华.序贯18F-FDG PET/CT显像在非手术治疗食管癌同步放化疗疗效预测中的价值[J].中华核医学与分子影像杂志,2013,33(6). 被引量:3
  • 2王小利,张春梅,施侣元,余红平,徐顺清.p53基因突变和蛋白表达改变在食管癌预后作用中的Meta分析[J].中华流行病学杂志,2004,25(9):769-774. 被引量:11
  • 3Fumiko Sunada,Masayuki Itabashi,Hisanao Ohkura,Toshiyuki Okumura.p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy[J].World Journal of Gastroenterology,2005,11(36):5696-5700. 被引量:13
  • 4孙伟,庞作良,斯刊达尔.阿布力孜,张国庆,高胜利,阿迪利.萨来,毛拉.艾沙.全胸段食管切除对胸下段食管癌患者术后生存率影响的临床研究[J].中华肿瘤防治杂志,2006,13(18):1418-1420. 被引量:3
  • 5程惠华,傅志超,林贵山,赖红斌.甘氨双唑钠对食管癌根治性放疗后复发再程放疗的增敏作用[J].第四军医大学学报,2007,28(1):39-41. 被引量:8
  • 6Francesco Cobelli,Francesco Giganti,Elena Orsenigo,Michaela Cellina,Antonio Esposito,Giulia Agostini,Luca Albarello,Elena Mazza,Alessandro Ambrosi,Carlo Socci,Carlo Staudacher,Alessandro Maschio.Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology[J]. European Radiology . 2013 (8)
  • 7Mark van Heijl,Jikke M. Omloo,Mark I. van Berge Henegouwen,Otto S. Hoekstra,Ronald Boellaard,Patrick M. Bossuyt,Olivier R. Busch,Hugo W. Tilanus,Maarten C. Hulshof,Ate van der Gaast,Grard A. Nieuwenhuijzen,Han J. Bonenkamp,John Th. Plukker,Miguel A. Cuesta,Fiebo J. ten Kate,Jan Pruim,Herman van Dekken,Jacques J. Bergman,Gerrit W. Sloof,J. Jan van Lanschot.Fluorodeoxyglucose Positron Emission Tomography for Evaluating Early Response During Neoadjuvant Chemoradiotherapy in Patients With Potentially Curable Esophageal Cancer[J]. Annals of Surgery . 2011 (1)
  • 8Johannes B. Roedl,Elkan F. Halpern,Rivka R. Colen,Dushyant V. Sahani,Alan J. Fischman,Michael A. Blake.Metabolic Tumor Width Parameters as Determined on PET/CT Predict Disease-free Survival and Treatment Response in Squamous Cell Carcinoma of the Esophagus[J]. Molecular Imaging and Biology . 2009 (1)
  • 9James M. McLoughlin,Marcovalerio Melis,Erin M. Siegel,E. Michelle Dean,Jill M. Weber,Jeannie Chern,Melanie Elliott,Scott T. Kelley,Richard C. Karl.Are Patients with Esophageal Cancer Who Become PET Negative after Neoadjuvant Chemoradiation Free of Cancer?[J]. Journal of the American College of Surgeons . 2008 (5)
  • 10Ichirou Higuchi,Takushi Yasuda,Masahiko Yano,Yuichirou Doki,Hiroshi Miyata,Mitsuaki Tatsumi,Hironori Fukunaga,Shuji Takiguchi,Yoshiyuki Fujiwara,Jun Hatazawa,Morito Monden.Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma[J]. The Journal of Thoracic and Cardiovascular Surgery . 2008 (1)

共引文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部